Search research articles
Contact Us
Filters
Showing results (241-250 of 255) with videos related to
Page
of 26
Sort By:
The Lancet. Psychiatry
|
November 13, 2025
Efficacy and safety of iclepertin for cognitive impairment associated with schizophrenia (CONNEX programme): results from three phase 3 randomised controlled trials
Richard S E Keefe, Philip D Harvey, Christoph U Correll, et al.
Schizophrenia Research
|
December 16, 2011
Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophrenia
Daniel C Javitt, Robert W Buchanan, Richard S E Keefe, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
|
June 19, 2021
Genome-wide association study accounting for anticholinergic burden to examine cognitive dysfunction in psychotic disorders
Seenae Eum, S Kristian Hill, Ney Alliey-Rodriguez, et al.
Translational Psychiatry
|
April 13, 2018
Polygenic risk for schizophrenia and measured domains of cognition in individuals with psychosis and controls
Rebecca Shafee, Pranav Nanda, Jaya L Padmanabhan, et al.
Journal of Clinical Psychopharmacology
|
June 18, 2015
Adjunctive Minocycline in Clozapine-Treated Schizophrenia Patients With Persistent Symptoms
Deanna L Kelly, Kelli M Sullivan, Joseph P McEvoy, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
|
April 28, 2006
Baseline neurocognitive deficits in the CATIE schizophrenia trial
Richard S E Keefe, Robert M Bilder, Philip D Harvey, et al.
The American Journal of Psychiatry
|
January 4, 2008
The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity
Keith H Nuechterlein, Michael F Green, Robert S Kern, et al.
Schizophrenia Research
|
September 14, 2013
Issues and perspectives in designing clinical trials for negative symptoms in schizophrenia
Stephen R Marder, Larry Alphs, Ion-George Anghelescu, et al.
Biological Psychiatry
|
December 15, 2010
A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia
Robert W Buchanan, Richard S E Keefe, Jeffrey A Lieberman, et al.
Schizophrenia Research
|
March 3, 2015
A Phase II study of a histamine H₃ receptor antagonist GSK239512 for cognitive impairment in stable schizophrenia subjects on antipsychotic therapy
L Fredrik Jarskog, Martin T Lowy, Richard A Grove, et al.
Page
of 26
Search research articles
Search
Showing results (241-250 of 255) with videos related to
Sort By:
Page
of 26
The Lancet. Psychiatry
|
November 13, 2025
Efficacy and safety of iclepertin for cognitive impairment associated with schizophrenia (CONNEX programme): results from three phase 3 randomised controlled trials
Richard S E Keefe, Philip D Harvey, Christoph U Correll, et al.
Schizophrenia Research
|
December 16, 2011
Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophrenia
Daniel C Javitt, Robert W Buchanan, Richard S E Keefe, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
|
June 19, 2021
Genome-wide association study accounting for anticholinergic burden to examine cognitive dysfunction in psychotic disorders
Seenae Eum, S Kristian Hill, Ney Alliey-Rodriguez, et al.
Translational Psychiatry
|
April 13, 2018
Polygenic risk for schizophrenia and measured domains of cognition in individuals with psychosis and controls
Rebecca Shafee, Pranav Nanda, Jaya L Padmanabhan, et al.
Journal of Clinical Psychopharmacology
|
June 18, 2015
Adjunctive Minocycline in Clozapine-Treated Schizophrenia Patients With Persistent Symptoms
Deanna L Kelly, Kelli M Sullivan, Joseph P McEvoy, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
|
April 28, 2006
Baseline neurocognitive deficits in the CATIE schizophrenia trial
Richard S E Keefe, Robert M Bilder, Philip D Harvey, et al.
The American Journal of Psychiatry
|
January 4, 2008
The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity
Keith H Nuechterlein, Michael F Green, Robert S Kern, et al.
Schizophrenia Research
|
September 14, 2013
Issues and perspectives in designing clinical trials for negative symptoms in schizophrenia
Stephen R Marder, Larry Alphs, Ion-George Anghelescu, et al.
Biological Psychiatry
|
December 15, 2010
A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia
Robert W Buchanan, Richard S E Keefe, Jeffrey A Lieberman, et al.
Schizophrenia Research
|
March 3, 2015
A Phase II study of a histamine H₃ receptor antagonist GSK239512 for cognitive impairment in stable schizophrenia subjects on antipsychotic therapy
L Fredrik Jarskog, Martin T Lowy, Richard A Grove, et al.
Page
of 26